35 studies found for:    "Cutaneous mastocytosis"
Show Display Options
Rank Status Study
21 Unknown  Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Advanced Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
22 Completed Study on Mastocytosis for Rupatadine Treatment
Condition: Mastocytosis
Intervention: Drug: Rupatadin
23 Completed A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive);   Hypereosinophilic Syndrome;   Systemic Mastocytosis
Intervention: Drug: Nilotinib
24 Completed Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Conditions: Nonneoplastic Condition;   Precancerous Condition
Intervention: Drug: thalidomide
25 Completed Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Conditions: Mastocytosis;   Anaphylaxis
Intervention:
26 Recruiting Study of Mast Cell Precursors
Condition: Mastocytosis
Intervention:
27 Completed Characteristics of Mast Cells in Mastocytosis
Condition: Mastocytosis
Intervention:
28 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
29 Recruiting Use of Tamoxifen in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention:
30 Completed Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Condition: Patients With Mastocytosis With Handicap and Bearing Mutations Asp-816-Val (D816V)
Intervention: Drug: masitinib
31 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
32 Unknown  Molecular Mechanisms and Diagnosis of Mastocytosis
Condition: Mastocytosis
Intervention:
33 Completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Nonneoplastic Condition;   Precancerous Condition
Intervention: Drug: tanespimycin
34 Completed Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Condition: Mastocytosis
Intervention: Drug: masitinib (AB1010)
35 Terminated Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter
Conditions: Malignant Mast Cell Tumors;   Solid Organ Sites
Intervention: Other: QUALITY OF LIFE QUESTIONNAIRE

Show previous page of results Previous Page (1-20) Studies Shown (21-35) Next Page
Indicates status has not been verified in more than two years